These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 25098784)

  • 1. Discovering the sympathomodulatory properties of new calcium channel blockers: an exciting but still snaky journey.
    Grassi G
    J Hypertens; 2014 Sep; 32(9):1780-1. PubMed ID: 25098784
    [No Abstract]   [Full Text] [Related]  

  • 2. Differential effects of azelnidipine and amlodipine on sympathetic nerve activity in patients with primary hypertension.
    Inomata J; Murai H; Kaneko S; Hamaoka T; Ikeda T; Kobayashi D; Usui S; Furusho H; Sugiyama Y; Takata S; Takamura M
    J Hypertens; 2014 Sep; 32(9):1898-904. PubMed ID: 24979307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Calcium antagonists: current and future applications based on new evidence. Calcium channel blockers and autonomic nervous system].
    Hirooka Y; Sunagawa K
    Clin Calcium; 2010 Jan; 20(1):32-7. PubMed ID: 20048431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats.
    Shokoji T; Fujisawa Y; Kiyomoto H; Rahman M; Sun GP; Fan YY; Kimura S; Kohno M; Abe Y; Nishiyama A
    Hypertens Res; 2005 Dec; 28(12):1017-23. PubMed ID: 16671342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Novel actions of calcium channel blockers].
    Kumagai H; Onami T; Takimoto C; Iigaya K; Hayashi K
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():311-7. PubMed ID: 16983770
    [No Abstract]   [Full Text] [Related]  

  • 6. Chronotropic effects of azelnidipine, a slow- and long-acting dihydropyridine-type calcium channel blocker, in anesthetized dogs: a comparison with amlodipine.
    Fujisawa M; Yorikane R; Chiba S; Koike H
    J Cardiovasc Pharmacol; 2009 Apr; 53(4):325-32. PubMed ID: 19295444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of azelnidipine and amlodipine on exercise-induced sympathoexcitation assessed by pupillometry in hypertensive patients.
    Koike Y; Kawabe T; Nishihara K; Iwane N; Hano T
    Hypertens Res; 2016 Dec; 39(12):863-867. PubMed ID: 27439493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study.
    Lefrandt JD; Heitmann J; Sevre K; Castellano M; Hausberg M; Fallon M; Fluckiger L; Urbigkeit A; Rostrup M; Agabiti-Rosei E; Rahn KH; Murphy M; Zannad F; de Kam PJ; van Roon AM; Smit AJ
    Am J Hypertens; 2001 Nov; 14(11 Pt 1):1083-9. PubMed ID: 11724204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity.
    Nagasu H; Satoh M; Fujimoto S; Tomita N; Sasaki T; Kashihara N
    Hypertens Res; 2012 Mar; 35(3):348-55. PubMed ID: 22072106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L/T-type and L/N-type calcium-channel blockers attenuate cardiac sympathetic nerve activity in patients with hypertension.
    Ogura C; Ono K; Miyamoto S; Ikai A; Mitani S; Sugimoto N; Tanaka S; Fujita M
    Blood Press; 2012 Dec; 21(6):367-71. PubMed ID: 22747420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
    Konno S; Hirooka Y; Araki S; Koga Y; Kishi T; Sunagawa K
    J Cardiovasc Pharmacol; 2008 Dec; 52(6):555-60. PubMed ID: 19057394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure.
    Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Fukuda T; Numao T; Shimada K; Kario K
    J Cardiovasc Pharmacol; 2007 Jun; 49(6):394-400. PubMed ID: 17577104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats.
    Aritomi S; Harada E; Sugino K; Nishimura M; Nakamura T; Takahara A
    Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):344-52. PubMed ID: 25582553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The newly developed calcium antagonist, azelnidipine, increases drain volume in continuous ambulatory peritoneal dialysis patients.
    Suzuki H; Inoue T; Kobayashi K; Shoda J; Nakamoto H
    Adv Perit Dial; 2006; 22():18-23. PubMed ID: 16983932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity.
    Kimura Y; Hirooka Y; Sagara Y; Sunagawa K
    Clin Exp Hypertens; 2007 Jan; 29(1):13-21. PubMed ID: 17190727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azelnidipine.
    Wellington K; Scott LJ
    Drugs; 2003; 63(23):2613-21; discussion 2623-4. PubMed ID: 14636080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of azelnidipine and amlodipine on single cell mechanics in mouse cardiomyocytes.
    Iribe G; Kaihara K; Ito H; Naruse K
    Eur J Pharmacol; 2013 Sep; 715(1-3):142-6. PubMed ID: 23747592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some similarities and differences between verapamil and the dihydropyridines.
    Antonios TF; MacGregor GA
    J Hypertens Suppl; 1998 Jan; 16(1):S31-4. PubMed ID: 9534094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacological differences in antianginal effects of long-lasting calcium channel blockers: azelnidipine and amlodipine.
    Fujisawa M; Yorikane R; Matsuoka Y; Koike H; Ueno K
    J Cardiovasc Pharmacol; 2013 Jan; 61(1):63-9. PubMed ID: 23288106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertension in older adults: progress and limitations.
    Rich MW
    Am J Med; 2012 Oct; 125(10):949-50. PubMed ID: 22902034
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.